After beefing up the target of its global cost-savings drive once again, Pfizer is continuing to see its plan through with ...
After three decades spent rising through the ranks of sales and marketing teams at major pharmas, Chris Boulton is taking the ...
Abbott has put the ball back in Serena Williams’ court to serve up a high-profile endorsement of the Lingo over-the-counter ...
European legislators have reached a deal on a major rewrite of the region's pharma policies, pushing forward a framework ...
After winning an approval decades in the making last year—and shuffling its executive roster throughout 2025—Geron ...
About a year and a half after telegraphing plans to shift its headquarters from New Jersey to Philadelphia, CDMO Adare Pharma ...
The FDA has issued its stamp of approval to a new, cell-based option to treat Wiskott-Aldrich syndrome (WAS), marking the ...
Gamida Cell has scored an expansion for Omisirge, with the FDA endorsing the stem cell-based therapy to treat severe aplastic ...
A proposed combination of Johnson & Johnson’s multiple myeloma bispecific Tecvayli has turned up positive trial data that ...
With a new edition of a long-running awareness campaign, Genentech is drawing attention to the talents and passions that are ...
The new Lilly facilities—which include a $5 billion API plant near Richmond, Virginia, which was announced in September—are ...
Biosecure Act slips into key US defense bill, teeing up potential China biopharma constraints in '26
While the China-targeting Biosecure Act failed to pass muster in a key defense spending bill last year, a retooled version of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback